Abstract 3888: <i>TOP1</i> mutations mediate cross resistance to ADCs in metastatic breast cancer
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(Harvard University), Beverly Moy(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Bogang Wu(George Washington University), Seth A. Wander(Massachusetts General Hospital), Ryan B. Corcoran(Harvard University), Arielle J. Medford(Harvard University), Andreas Varkaris(Beth Israel Deaconess Medical Center), Haley Barnes(Massachusetts General Hospital), Leif W. Ellisen(Harvard University), Geoffrey Fell(Harvard University), Caroline Weipert(Guardant (United States)), Dejan Juric(Massachusetts General Hospital), Annika Putur(Massachusetts General Hospital)
Cited by 2
Related Papers
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
|Nature Communications|2017|999
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2010|983
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846